Wayne Winegarden
Commentary
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
Wayne Winegarden
October 22, 2019
Climate Change
Policies Should Address Global Climate Change By Incenting Innovation
Amidst all of the rhetoric and dire predictions surrounding global climate change, it is easy to lose one’s perspective. But, we will not successfully minimize the risks created by global climate change without perspective. Fundamental to this perspective, U.S. greenhouse gas (GHG) emissions have been declining for more than a ...
Wayne Winegarden
October 4, 2019
Business & Economics
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Wayne Winegarden
October 2, 2019
Business & Economics
Why Is Sen. Schumer Suddenly Decrying High Tax Rates?
Senate Minority Leader Charles Schumer, D-New York, recently stood in front of a home in a beautiful neighborhood in White Plains, NY, to decry — of all things — the area’s high local tax burden. “We all know that one of the biggest burdens to live in this beautiful place ...
Wayne Winegarden
September 5, 2019
California
‘Pay-for-Delay’ Generic Drug Bill Will Harm Californians
San Diegans and all Californians will pay a high price should a bill introduced by Assemblyman Jim Wood, a Democrat from Santa Rosa, become law. Proponents claim the bill is necessary to rein in anti-competitive practices by the pharmaceutical industry, but in reality, it will delay generic entry and raise the ...
Wayne Winegarden
August 27, 2019
Commentary
More Competition Will Improve Drug Affordability
Making medicines more affordable for patients promises to be a top policy priority for Congress when it returns from its August recess. Achieving this goal does not require new, elaborate, government programs or regulations. It requires reforms that will empower biosimilars to more effectively compete against originator biologics. To see ...
Wayne Winegarden
August 26, 2019
Business & Economics
Sacramento, not D.C., is responsible for California’s unaffordable tax burden
Last fall, Democratic congressional candidates successfully painted the 2017 federal Tax Cuts and Jobs Act as a tax increase on hard working Californians to pick-up even more congressional seats. Congress, they charged, raised the tax burden of many Californians by, among other things, capping the State and Local Tax, or ...
Wayne Winegarden
August 21, 2019
Business & Economics
Making It Rain In California
The “Tax Cuts and Jobs Act” (TCJA) was signed into law on Dec. 22, 2017. The Act reformed the U.S. corporate income tax code cutting the rate to a globally competitive 21%. Reforms on the personal income tax side, which are scheduled to expire in 2025, reduced the marginal income ...
Wayne Winegarden
August 19, 2019
Environment
Wine Winegarden Talks Colorado’s CLEAR vehicle emission plan on the Americhiks with Kim Monson
Wayne Winegarden joins the Americhiks with Kim Monson to discuss Colorado’s new CLEAR vehicle emission regulations.
Wayne Winegarden
August 15, 2019
Drug Pricing
What to Know in Washington: When Drugs Make News, Trump Reacts
Staffers at the Department of Health and Human Services have gotten used to a pattern: President Donald Trump sees a news report on spikes in prescription-drug list prices, Secretary Alex Azar is called to a meeting in the Oval Office, and a policy in the discussion stage gets accelerated and ...
Wayne Winegarden
August 15, 2019
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
Policies Should Address Global Climate Change By Incenting Innovation
Amidst all of the rhetoric and dire predictions surrounding global climate change, it is easy to lose one’s perspective. But, we will not successfully minimize the risks created by global climate change without perspective. Fundamental to this perspective, U.S. greenhouse gas (GHG) emissions have been declining for more than a ...
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Why Is Sen. Schumer Suddenly Decrying High Tax Rates?
Senate Minority Leader Charles Schumer, D-New York, recently stood in front of a home in a beautiful neighborhood in White Plains, NY, to decry — of all things — the area’s high local tax burden. “We all know that one of the biggest burdens to live in this beautiful place ...
‘Pay-for-Delay’ Generic Drug Bill Will Harm Californians
San Diegans and all Californians will pay a high price should a bill introduced by Assemblyman Jim Wood, a Democrat from Santa Rosa, become law. Proponents claim the bill is necessary to rein in anti-competitive practices by the pharmaceutical industry, but in reality, it will delay generic entry and raise the ...
More Competition Will Improve Drug Affordability
Making medicines more affordable for patients promises to be a top policy priority for Congress when it returns from its August recess. Achieving this goal does not require new, elaborate, government programs or regulations. It requires reforms that will empower biosimilars to more effectively compete against originator biologics. To see ...
Sacramento, not D.C., is responsible for California’s unaffordable tax burden
Last fall, Democratic congressional candidates successfully painted the 2017 federal Tax Cuts and Jobs Act as a tax increase on hard working Californians to pick-up even more congressional seats. Congress, they charged, raised the tax burden of many Californians by, among other things, capping the State and Local Tax, or ...
Making It Rain In California
The “Tax Cuts and Jobs Act” (TCJA) was signed into law on Dec. 22, 2017. The Act reformed the U.S. corporate income tax code cutting the rate to a globally competitive 21%. Reforms on the personal income tax side, which are scheduled to expire in 2025, reduced the marginal income ...
Wine Winegarden Talks Colorado’s CLEAR vehicle emission plan on the Americhiks with Kim Monson
Wayne Winegarden joins the Americhiks with Kim Monson to discuss Colorado’s new CLEAR vehicle emission regulations.
What to Know in Washington: When Drugs Make News, Trump Reacts
Staffers at the Department of Health and Human Services have gotten used to a pattern: President Donald Trump sees a news report on spikes in prescription-drug list prices, Secretary Alex Azar is called to a meeting in the Oval Office, and a policy in the discussion stage gets accelerated and ...